Novo Nordisk A/ S stock (DK0060534915): Up 1.29% to $47 amid recovery trend

Novo Nordisk A/S (NVO) stock advanced 1.29% to $47.00 during recent trading on the NYSE, with volume reaching 14.25 million shares. The price pressed against the $47 horizontal resistance after recovering from an early-April low of $35.10, up significantly year-to-date despite a 7.7% decline from January 2026 levels of $50.88, AJ Bell as of May 13, 2026 and FXStreet as of May 13, 2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Novo Nordisk A/S: core business model

Novo Nordisk A/S specializes in diabetes care and chronic disease treatments, with a portfolio centered on insulin therapies and GLP-1 receptor agonists. The company develops, manufactures, and markets pharmaceuticals addressing diabetes, obesity, hemophilia, and growth disorders. Its business model relies on innovation in biologics, global distribution through partnerships, and a strong presence in the US market via its NYSE-listed ADRs.

Headquartered in Denmark, Novo Nordisk generates substantial revenue from the US, where demand for its blockbuster drugs drives growth. The firm's R&D focuses on next-generation therapies, supported by a direct-to-consumer approach in key markets.

Main revenue and product drivers for Novo Nordisk A/S

Key products include Ozempic and Wegovy, GLP-1 drugs for diabetes and weight management, which have fueled revenue expansion. In recent quarters, these semaglutide-based treatments have dominated sales, with the US accounting for over half of total revenue. The obesity segment has emerged as a major growth driver amid rising demand.

Diabetes care remains the core, with insulin products like Tresiba contributing steadily. Novo Nordisk's pipeline emphasizes cardiovascular and kidney disease outcomes tied to its GLP-1 franchise, enhancing its appeal to US healthcare providers and payers.

Industry trends and competitive position

The GLP-1 market is expanding rapidly due to obesity epidemic trends in the US, where Novo Nordisk holds a leading share against competitors like Eli Lilly. Patent protections and manufacturing scale provide a competitive edge, though supply constraints have impacted growth. Sector data from IQVIA highlights GLP-1 prescriptions surging in the US.

Why Novo Nordisk A/S matters for US investors

Novo Nordisk A/S offers US investors exposure to the booming US obesity and diabetes markets via its NYSE ADR listing. With significant revenue from American prescriptions and clinical trials, the stock reflects US healthcare spending trends and payer dynamics, making it relevant for portfolios tracking biotech innovation.

Conclusion

Novo Nordisk A/S stock recently gained 1.29% to test $47 resistance amid a recovery from April lows, reflecting ongoing interest in its GLP-1 portfolio. While year-to-date declines from 2026 peaks show volatility, the company's US market exposure and product momentum remain key factors. Investors track technical levels and volume for near-term direction.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.